ArticleJournal of clinical epidemiology2021
Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials.
Article in Journal of clinical epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Biological research on mental pain, social pain and other pains not primarily felt in the body: methodological systematic review.The British journal of psychiatry : the journal of mental science · 2025Pooled it
- Overlapping research efforts in a global pandemic: a rapid systematic review of COVID-19-related individual participant data meta-analyses.BMC health services research · 2023Pooled it
- Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- Reliability of Trial Information Across Registries for Trials With Multiple Registrations: A Systematic Review.JAMA network open · 2021Pooled it
- Clinical trials and their impact on policy during COVID-19: a review.Wellcome open research · 2024Review
- Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Validation of 3D-Printed Swabs for Sampling in SARS-CoV-2 Detection: A Pilot Study.Annals of biomedical engineering · 2023Article
- Estimating the effect of COVID-19 on trial design characteristics: a registered report.Royal Society open science · 2023Article
- Transparency and reporting characteristics of COVID-19 randomized controlled trials.BMC medicine · 2022Article
- Toward an observatory of the evolution of clinical trials through phylomemy reconstruction: the COVID-19 vaccines example.Journal of clinical epidemiology · 2022Article
- Article
- Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study.BMJ open · 2021Article
- Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study.Systematic reviews · 2021Article
- Ethical considerations of the dynamics of clinical trials in an epidemic context: Studies on COVID-19.Ethics, medicine, and public health · 2021Article
- Reading, Conducting, and Developing Systematic Review and Individual Patient Data Meta-Analyses in Psychiatry for Treatment Issues.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesResearchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. STUDY DESIGN AND
settingWe performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered.
resultsBy August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1-Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33-67]; 15-163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients.
conclusionThis living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.